Evidence map›Paper›PMID 31401767›Full record

ArticleInternational journal of hematology2019

Bortezomib-containing therapy in Japanese children with relapsed acute lymphoblastic leukemia.

Daisuke Hasegawa, Yuri Yoshimoto, Shunsuke Kimura, Tadashi Kumamoto, Naoko Maeda, Junichi Hara, Atsushi Kikuta, Akiko Kada, Toshimi Kimura, Yuka Iijima-Yamashita and 4 more

Abstract readClinical Trial, Phase I
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Daisuke HasegawaDepartment of Pediatrics, St. Luke's International Hospital, 9-1, Akashi-cho, Chuo-ku, Tokyo, 104-8560, Japan. hase-dai@umin.net.ORCID http://orcid.org/0000-0002-9446-9568
Yuri YoshimotoDepartment of Pediatrics, St. Luke's International Hospital, 9-1, Akashi-cho, Chuo-ku, Tokyo, 104-8560, Japan.
Shunsuke KimuraDepartment of Pediatrics, St. Luke's International Hospital, 9-1, Akashi-cho, Chuo-ku, Tokyo, 104-8560, Japan.
Tadashi KumamotoDepartment of Pediatrics, St. Luke's International Hospital, 9-1, Akashi-cho, Chuo-ku, Tokyo, 104-8560, Japan.
Naoko MaedaDepartment of Pediatrics, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Junichi HaraDepartment of Pediatric Hematology and Oncology, Osaka City General Hospital, Osaka, Japan.
Atsushi KikutaDepartment of Pediatric Oncology, Fukushima Medical University Hospital, Fukushima, Japan.
Akiko KadaClinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Toshimi KimuraDepartment of Pharmacy, Tokyo Women's Medical University Hospital, Tokyo, Japan.
Yuka Iijima-YamashitaClinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Akiko M SaitoClinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Keizo HoribeClinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Atsushi ManabeDepartment of Pediatrics, St. Luke's International Hospital, 9-1, Akashi-cho, Chuo-ku, Tokyo, 104-8560, Japan.
Chitose OgawaDepartment of Pediatric Oncology, National Cancer Center Hospital, Tokyo, Japan.
National Hospital Organization · JPSt. Luke's International Hospital · JPFukushima Medical University Hospital · JPOsaka City General Hospital · JPTokyo Women's Medical University Hospital · JP

Funding

Japan Agency for Medical Research and Development JP17ck0106110
6 · The paper itself

Abstract

Outcomes of children treated for relapsed acute lymphoblastic leukemia (ALL) remain poor. Bortezomib (BZM), a proteasome inhibitor, has shown promising activity against lymphoid malignancies. We conducted a phase I study to evaluate the safety and tolerability of multidrug chemotherapy including BZM in Japanese children with relapsed ALL. Three of five children with relapsed ALL enrolled in the study between November 2014 and April 2016 were evaluated. BZM (1.3 mg/m

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBortezomibChildChild, PreschoolHumansJapanMaximum Tolerated DosePrecursor Cell Lymphoblastic Leukemia-LymphomaRecurrenceSalvage TherapyTreatment OutcomeBortezomibAcute lymphoblastic leukemiaBortezomibChildrenCombination chemotherapyRelapse

Identifiers

PMID31401767
OpenAlexW2967829643

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.